Norcross, GA, USA – September 30th, 2014 – AKESOgen announced today that it has been awarded a $7.5M contract by the U.S. Department of Veterans Affairs (VA) for genotyping samples from U.S. veterans as part of the Million Veteran Program (MVP). This award covers the genotyping of 109,000 veterans in the second year of a five year contract.
“We were delighted to provide theVA with the first tranche of data that consisted of genotyping 105,000 veterans. We now look forward to genotyping an additional 109,000 veterans to enrich the existing data sets in year 2,” said Mark Bouzyk, CSO of AKESOgen
To learn more about AKESOgen, please visit www.akesogen.com.
About AKESOgen, Inc.
AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.
About the VA Million Veteran Program
Launched in 2011, MVP is a landmark research effort aimed at better understanding how genes affect health. Up to a million Veterans are expected to enroll in the VA study over the next 5-6 years. Data and genetic samples collected through the study are stored securely and made available for studies by authorized researchers, with stringent safeguards in place to protect Veterans’ private health information. MVP is now enrolling at over 50 VA medical centers nationwide. The VA’s central bio-repository is equipped with a state-of-the-art robotic system for DNA extraction and storage and is currently being expanded to support up to 4 million samples. With more than 240,000 enrollees to date, MVP already far exceeds the enrollment numbers of any single VA study or research program in the past. MVP provides researchers with a rich resource of genetic, health, lifestyle, and military-exposure data collected from questionnaires, medical records, and genetic analyses. By combining this information into a single database, MVP promises to advance knowledge about the complex links between genes and health. Veterans’ privacy and confidentiality are top priorities in MVP, as in all VA research. For more information about MVP, visit www.research.va.gov/MVP
Mark Bouzyk, PhD, Chief Scientific Officer
404 771 8667